How plausible is a link between HSV-1 infection and Alzheimer's disease?

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 3, 2014, Pages 275-278

  Agostini, Simone ^a   Clerici, Mario ^a,b   Mancuso, Roberta ^a  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimers disease; HSV 1; humoral immunity; intravenous immunoglobulin; MRI

Indexed keywords

ALZHEIMER DISEASE; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS;

EID: 84894205406     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.887442     Document Type: Review

References (28)

1. Ball MJ, Lukiw WJ, Kammerman EM, Hill JM. Intracerebral propagation of Alzheimer's disease: strengthening evidence of a herpes simplex virus etiology. Alzheimers Dement 2013;9(2):169-75
2. Licastro F, Carbone I, Ianni M, Porcellini E. Gene signature in Alzheimer's disease and environmental factors: the virus chronicle. J Alzheimers Dis 2011;27(4):809-17
3. Honjo K, Van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement 2009;5(4):348-60
4. Letenneur L, Peres K, Fleury H, et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS One 2008;3(11):e3637
5. Kobayashi N, Nagata T, Shinagawa S, et al. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. Biochem Biophys Res Commun 2013;430(3):907-11
6. Jamieson GA, Maitland NJ, Wilcock GK, et al. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol 1991;33(4):224-7
7. Dedicoat M, Muir D. Viral meningitis- or encephalitis? Practitioner 1998;242(1587):489-92
8. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett 2007;429(2-3):95-100
9. De Chiara G, Marcocci ME, Civitelli L, et al. APP processing induced by herpes simplex virus type 1 (HSV-1) yelds several APP fragments in human and rat neuronal cells. PLoS One 2010;5(11):e13989
10. Alvarez G, Aldudo J, Alonso M, et al. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res 2012;90(5):1020-9
11. Martin C, Aguila B, Araya P, et al. Inflammatory and neurodegeneration markers during asymptomatic HSV-1 reactivation. J Alzheimers Dis 2013. [Epub ahead of print]
12. Cheng SB, Ferland P, Webster P, Bearer EL. Herpes simplex virus dances with amyloid precursor protein while exiting the cell. PLoS One 2011;6(3):e17966
13. Santana S, Recuero M, Bullido MJ, et al. Herpes simplex virus type I induces the accumulation of intracellular b-amyloid in autophagic compartments and the inhibition of the non-amyloidogenic pathway in human neuroblastoma cells. Neurobiol Aging 2012;33(2):430.e19-33
14. Sokolov AA, Reincke M. Herpes simplex encephalitis affecting the entire limbic system. Mayo Clin Proc 2012;87(9):e69
15. Burgos JS, Ramirez C, Sastre I, Valdivieso F. Apolipoprotein E genotype influences vertical transmission of herpes simplex virus type 1 in a gender specific manner. Aging Cell 2007;6(6):841-2
16. Saldanha J, Sutton RN, Gannicliffe A, et al. Detection of HSV1 DNA by in situ hybridisation in human brain after immunosuppression. J Neurol Neurosurg Psychiatry 1986;49(6):613-19
17. Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Reactivation of herpes simplex virus type 1 is associated with cytomegalovirus and age. J Med Virol 2012;84(11):1797-802
18. Mancuso R, Baglio F, Cabinio M, et al. Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in alzheimer's disease. J Alzheimers Dis 2014;38(4):741-5
19. Del Valle J, Duran-Vilaregut J, Manich G, et al. Time-course of blood-brain barrier disruption in senescence-accelerated mouse prone 8 (SAMP8) mice. Int J Dev Neurosci 2009;27(1):47-52
20. Pelegri C, Canudas AM, Del Valle J, et al. Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev 2007;128(9):522-8
21. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012;11(10):868-77
22. Erlich KS, Mills J. Passive immunotherapy for encephalitis caused by herpes simplex virus. Rev Infect Dis 1986;8(Suppl 4):S439-45
23. Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009;73(3):180-5
24. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30(11):1728-36
25. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(10):1472-4
26. Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-beta to tau. Nat Rev Neurol 2013;9(12):677-86
27. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12(3):233-43
28. Wozniak MA, Itzhaki RF. Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1. J Neuroimmunol 2013;257(1-2):7-12